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Abstract
Mutations in the KCNA1 gene encoding the voltage-gated 
potassium (K+) channel Kv1.1 have been linked to rare neu-
rological syndromes, episodic ataxia type 1 (EA1) and myo-
kymia. In 2009, a KCNA1 mutation was identified in a large 
family with autosomal dominant hypomagnesemia. Despite 
efforts in establishing a genotype-phenotype correlation for 
the wide variety of symptoms in EA1, little is known on the 
serum magnesium (Mg2+) levels in these patients. In the 
present study, we describe a new de novo KCNA1 mutation 
in a Polish patient with tetany and hypomagnesemia. Elec-
trophysiological and biochemical analyses were performed 
to determine the pathogenicity of the mutation. A female 
patient presented with low serum Mg2+ levels, renal Mg2+ 
wasting, muscle cramps, and tetanic episodes. Whole exome 
sequencing identified a p.Leu328Val mutation in KCNA1 en-
coding the Kv1.1 K+ channel. Electrophysiological examina-
tions demonstrated that the p.Leu328Val mutation caused a 
dominant-negative loss of function of the encoded Kv1.1 
channel. Cell surface biotinylation showed normal plasma 
membrane expression. Taken together, this is the second re-
port linking KCNA1 with hypomagnesemia, thereby empha-
sizing the need for further evaluation of the clinical pheno-
types observed in patients carrying KCNA1 mutations.
© 2018 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Hypomagnesemia (serum magnesium [Mg2+] <0.7 
mmol/L) is a common electrolyte disorder that is caused 
by insufficient Mg2+ intake, the use of certain types of 
drugs, and/or genetic defects [1]. Over the last 15 years, 
studying the hereditary forms of hypomagnesemia has 
resulted in the identification of genes involved in the reg-
ulation of Mg2+ homeostasis [1, 2]. Many of the hypo-
magnesemia-causing gene mutations result in the defec-
tive reabsorption of Mg2+ in the distal convoluted tubule 
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(DCT) of the kidney. As renal Mg2+ reabsorption does not 
take place beyond the DCT, defects in this segment in-
evitably result in renal Mg2+ wasting.
In 2009, we identified a c.763A>G mutation in KCNA1, 
encoding the voltage-gated potassium (K+) channel 
Kv1.1, in a large family with tetany, muscle cramps, and 
severe hypomagnesemia [3]. The identified variant re-
sults in a p.Asn255Asp missense mutation that complete-
ly abolishes the channel activity despite normal plasma 
membrane localization [3, 4]. Within the kidney, Kv1.1 is 
exclusively found at the apical membrane of DCT cells [3, 
5]. It is hypothesized that Kv1.1 activity sets the driving 
force for active Mg2+ reabsorption via the Mg2+-perme-
able channel TRPM6.
Since the description of the first family in 2009, new 
hypomagnesemia-causing KCNA1 mutations have not 
been reported. Originally, KCNA1 mutations have been 
associated with episodic ataxia type 1 (EA1; MIM 
#160120), which is a rare neurological disorder character-
ized by motor discoordination, involuntary muscle con-
traction (myokymia), and seizures. While a recent geno-
type-phenotype correlation study in a large cohort of EA1 
patients demonstrated high inter- and intrafamilial vari-
ability of symptoms, the penetrance of the hypomagnese-
mia phenotype has not been assessed in EA1 [6]. 
Here, we present a novel KCNA1 mutation in a family 
with tetany and hypomagnesemia for the first time since 
the initial report. We determined the pathogenicity of the 
mutation using electrophysiological and biochemical 
analyses.
Subjects and Methods
Patients
All patient studies were performed in accordance with the 
guidelines of the Declaration of Helsinki. The local Ethics Com-
mittee approved the study and the patient and her relatives pro-
vided written informed consent for genetic analysis. Serum and 
urine electrolyte measurements were performed by general labora-
tory screenings. 
Microsatellite Analysis for Fatherhood Determination
To ascertain fatherhood, blood genomic DNA samples from 
the patient and both parents were PCR-amplified using prim-
ers  surrounding polymorphic microsatellite loci D15S1018 
 (AFMb332yc5), D9S1784 (AFMa136xa5), D12S1604 (AF-
Ma189yd9), D12S1590 (AFMa119wh5), D17S1529 (AFM022xb6), 
D8S405 (UT5312), and D9S172 (AFM199xf10). Primer sequences 
are provided in online supplementary Table S1 (for all online sup-
pl. material, see www.karger.com/doi/10.1159/000488954). Sam-
ples were subjected to capillary electrophoresis; data were analyzed 
with the GeneMapper software version 5 (Applied Biosystems).
Whole Exome Sequencing
DNA from whole blood was extracted according to standard 
protocols. Exome sequencing was performed from 200 ng of ge-
nomic DNA using the standard protocol SureSelectXT Automat-
ed Target Enrichment for Illumina paired-end multiplexed se-
quencing, and the Agilent Bravo automated liquid handling plat-
form. After validation (2200 TapeStation; Agilent Technologies, 
CA, USA) and quantification (Qubit System; Invitrogen, Waltham, 
MA, USA), pools of 6 libraries each were generated and subse-
quently sequenced on an Illumina HiSeq 4000 sequencing instru-
ment using a paired-end 2 ×  75 bp protocol.
For data analysis, the VARBANK pipeline version 2.15 (un-
published) and the corresponding filter interface was used. Raw 
reads were mapped to the human genome reference-build hg19 
using the Burrows Wheeler Aligner alignment algorithm with a 
base quality threshold of 15 for read trimming (parameter: -q 15) 
[7]. The resulting binary alignment map files were further pro-
cessed by Picard version 1.64 (http://broadinstitute.github.io/
picard/) to mark duplicate reads and GATK version 1.6 to perform 
local realignment around short insertions and deletions and to re-
calibrate the base-calling quality scores [8]. A mean coverage of 
76× was achieved with 84.6% of target regions covered more than 
30×. The data were filtered for high-quality rare (MAF < 0.001) 
autosomal variants and attention was focused on genes with 
known involvement in renal Mg2+ handling. 
Sanger Sequencing
The presence of the KCNA1 mutation p.Leu328Val was 
checked by the polymerase chain reaction using primers designed 
on the second exon of the human KCNA1 gene (NM_000217.2, F: 
5′-GGCCATCCTCAGGGTCATCC-3′, R: 5′-AGCATCGGG GAT 
ACTGGAGAA-3′). Amplified sequences were Sanger sequenced 
according to standard methods.
DNA Constructs
The human KCNA1 pCIneo IRES GFP plasmid (Kv1.1 wild 
type) was obtained as previously described [3]. The p.Leu328Val 
mutation was introduced using the QuickChange site directed mu-
tagenesis following the manufacturer’s protocol (Stratagene, La 
Jolla, CA, USA). The empty pCIneo IRES GFP construct was used 
as a control (mock) in the experiments.
Cell Culture 
HEK293 (human embryonic kidney 293) cells were cultured in 
Dulbeccos modified Eagles medium (DMEM, Bio Whittaker Eu-
rope, Vervier, Belgium) supplemented with 10% (v/v) fetal calf se-
rum (PAA, Linz, Austria), 2 mM L-glutamine, and 10 μL/mL non-
essential amino acids at 37  ° C in a humidity controlled incubator 
with 5% (v/v) CO2. The cells were transiently transfected with the 
respective DNA constructs using Lipofectamin 2000 (Invitrogen-
Life Technologies, Bleiswijk, The Netherlands). The cells were cul-
tured for 48 h prior to the start of experiments. For cell surface 
biotinylation, HEK293 cells were seeded on poly-L-lysine-coated 
6-well plates.
Electrophysiology
Whole-cell recordings from transfected HEK293 cells were ob-
tained at room temperature (20–25  ° C) using an EPC10 patch clamp 
amplifier controlled by Patchmaster software (HEKA Elektronik, 
Lambrecht, Germany). Currents were digitized at 10 kHz and digi-
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tally filtered at 2.9 kHz. Patch pipettes were pulled from thin-walled 
borosilicate glass (Harvard Apparatus, March-Hugstetten, 
 Germany) with tip resistance of 2–4 MΩ when filled with pipette 
solution. Cell capacitance and access resistance were monitored us-
ing the automatic capacitance compensation of the Patchmaster 
software. Transfected cells were identified by their green fluores-
cence when illuminated at 480 nm. The pipette solution contained 
(mM): 140 KCl, 1 MgCl2, 0.1 CaCl2, 2 EGTA, 10 HEPES, and 1 Na2-
ATP (pH adjusted to 7.3 with KOH). The extracellular solution con-
tained (mM): 138 NaCl, 5.4 KCl, 1.2 MgCl2, 1 CaCl2, 10 EGTA, and 
10 glucose (pH adjusted to 7.3 with NaOH). Recorded Kv1.1 cur-
rents were evoked by 150 ms voltage steps to potentials between 
–100 and +50 mV from a holding potential of –80 mV. Voltage steps 
were delivered in 10 mV increments at 10 s intervals. Current-volt-
age relations were constructed using the sustained amplitude at the 
end of test pulses. Current densities were obtained by normalizing 
the current amplitude to the cell membrane capacitance. No leakage 
subtraction was performed and cells with visible changes in leakage 
currents during the course of study were excluded from further 
analysis. The analysis and display of the data were performed using 
Igor Pro software (WaveMetrics, Lake Oswego, OR, USA). 
Cell Surface Biotinylation
At 48 h after transfection, cells were washed twice with PBS-
CM (PBS supplemented with 1 mM MgCl2, 0.5 mM CaCl2) follow-
ing biotinylation of cell surface proteins using sulfo-NHS-LC-LC-
biotin (0.5 mg/mL, Pierce, Etten-Leur, The Netherlands) in PBS-
CM for 30 min at 4  ° C. Unreacted biotin was quenched using 0.1 % 
(w/v) BSA in PBS-CM. Next, cells were washed once with PBS 
(pH 7.5) and lysed in lysis buffer 50 mM Tris-HCl (pH 7.5), 150 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton X-100, 1 mM 
sodium orthovanadate, 10 mM sodium-glycerophosphate, 50 mM 
sodium fluoride, 10 mM sodium pyrophosphate, 0.27 M sucrose, 
and the freshly added protease inhibitors pepstatin A (1 μg/mL, 
MP Biomedicals, Santa Ana, CA, USA), PMSF (1 mM, Sigma Al-
drich, St Louis, MO, USA), leupeptin (5 μg/mL, MP Biomedicals), 
and aprotinin (1 μg/mL, Brunschwig Chemie, Basel, Switzerland). 
Cell lysates were collected and centrifuged (16,000 g) at 4  ° C for 
15 min. Protein concentration was determined using the Bradford 
method. Equal amounts of protein were incubated with neutravi-
din-agarose beads (Pierce) for 2 h at 4  ° C. The beads were washed 
3 times with lysis buffer and Kv1.1 was eluted with Laemmli sam-
ple buffer containing 100 mM DTT.
Immunoblotting
Kv1.1 expression was analyzed by immunoblot analysis for the 
input and the plasma membrane fraction using the Kv1.1 antibody 
(1: 3,000 Neuromab, Davis, CA, USA) and GFP antibody (1: 5,000, 
Sigma). Equal protein amounts were subjected to 10% (w/v) SDS-
PAGE gel, transferred to PDVF membrane (Millipore), and incu-
bated overnight with Kv1.1 antibody in TBS buffer supplemented 
with 0.1% Tween-20 (TBS-T) containing 5% (w/v) non-fat dry 
milk. Next day, the membranes were washed with TBS-T and in-
cubated for 60 min with horseradish peroxidase conjugated sec-
ondary goat anti-mouse antibody (1: 10,000, Chemie Brunschwig) 
and goat anti-rabbit antibody (1: 10,000, Sigma) for 1 h at room 
temperature. Subsequently, the membranes were washed with 
TBS-T, and proteins were visualized with the Biorad ChemiDoc 
XRS using chemiluminescence SuperSignal West reagent (Ther-
mo Fisher Scientific, Breda, The Netherlands).
Statistical Analysis
Data are shown as mean ± SEM. Statistical significance was de-
termined by analysis of variance Dunnett’s post hoc analysis using 
Prism software (GraphPad, San Diego, CA, USA). Differences in 
means with p < 0.05 were regarded as statistically significant. 
Results
Tetany and Hypomagnesemia in a Female Patient
The patient presented at age 4 with mild tetanic epi-
sodes, whose frequency and intensity slowly pro-
gressed  during follow-up. Significant hypomagnesemia 
(0.52 mmol/L) was first noted during pregnancy at the 
age of 24 years. Biochemical workup established a renal 
loss of Mg2+ (fractional excretion 3.9%, despite hypomag-
nesemia [normal < 1%]). No other biochemical abnor-
malities were observed, as the glomerular filtration rate, 
iPTH, plasma levels, and urinary excretion rates for Na+, 
Cl–, K+, Ca2+ and phosphate were in the normal range. 
She was treated with intravenous and oral Mg2+ and Ca2+ 
supplements. At present, at the age of 27 years, she re-
ceives oral Mg2+ supplements (390 mg of elemental Mg2+ 
per day), 1,000 mg of Ca2+ as well as 1000IE of vitamin 
D3. In addition, she is treated with hydrochlorothiazide 
and amiloride. However, therapy is only partially  effective. 
Despite a normalization of plasma Mg2+ (0.78 mmol/L) 
and total Ca2+ levels (2.43 mmol/L), she continues to be 
affected by ongoing tetanies of mouth, neck, and hands. 
In addition, she has repeated cramps of the lower extrem-
ities and constant muscular weakness. She occasionally 
receives tizanidine, a muscle relaxant. However, this 
treatment is insufficient to control persisting neuromus-
cular symptoms. Her parents, siblings, and daughter were 
examined for hypomagnesemia and tetanic symptoms 
(Fig. 1a). However, no abnormalities were found.
Microsatellite Analysis
Fatherhood was confirmed by analysis of 7 polymor-
phic microsatellite loci (for details see online suppl. 
 Table 1). 
De novo KCNA1-p.Leu328Val Mutation 
To identify genetic defects that could explain hypo-
magnesemia, we performed whole exome sequencing. 
After sequential filtering (frequency cut off: 0.001) and 
quality control, homozygous variants in 7 genes, com-
pound-heterozygous variants in 5 genes, as well as het-
erozygous variants in 223 genes were identified (for de-
tails see online suppl. Material). Filtering of the variants 
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including only hypomagnesemia-causing genes resulted 
in the identification of a heterozygous non-synonymous 
variant in KCNA1 (OMIM #176260, c.982C>G, p.Leu-
328Val; Fig. 1b). Especially, TRPM6, FXYD2, SLC12A3, 
CLDN16, CLDN19, EGF, CNNM2, HNF1B, and KCNJ10 
were negative for rare variants. The KCNA1-c.982C>G 
variant was absent in dbSNP, ExAC, and gnomAD data-
bases and was predicted to be deleterious by SIFT and 
PROVEAN [9–11]. Sanger sequencing of the parents did 
not detect mutations in KCNA1, indicating a de novo 
origin of the variant. KCNA1-p.Leu328 is highly con-
served among species (Fig. 1c). The KCNA1 gene codes 
for the voltage-gated K+ channel Kv1.1, which is com-
posed of 4 subunits each containing 6 transmembrane 
segments (S1–S6) and intracellular amino- and carboxy-
terminal tails (Fig. 1d). The p.Leu328Val mutation is lo-
cated at the base of the 5th transmembrane domain (S5), 
which is part of the channel pore (Fig. 1d). Previously, a 
homology model was developed (http://www.cmbi.ru.
nl/∼hvensela/Kv1.1/, [4]) that was based on the resolved 
chimaeric Kv1.2-Kv2.1 structure (PDB 2R9R [12]). Fig-
ure 1e shows the Kv1.1 homology model and depicts the 
transmembrane helices surrounding Leu328. This resi-
due is located on the surface of the S5 helix and was not 
found to be in contact with other domains. Of note, the 
mutant valine residue is smaller than the original leucine 
residue (Fig.  1e, green: original Leu328, red: mutant 
Val328).
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Fig. 1. KCNA1 mutation in a family with hypomagnesemia. a Ped-
igree of the family. Filled symbols represent affected individuals, 
the arrow indicates the proband. b Mutation analysis chromato-
gram of the proband. The mutation is indicated by an arrow. 
c Multiple alignment analysis shows conservation of the Leu328 
amino acid (blue bar) among species. The blue background indi-
cates a transmembrane region (TM5, based on human sequence). 
d Schematic overview of a subunit of the Kv1.1 channel. The red 
dot indicates the location of the mutation. e Localization of the 
p.Leu328Val mutation in the Kv1.1 protein structure (Uniprot 
Q09470).
Co
lor
 ve
rsi
on
 av
ail
ab
le 
on
lin
e
KCNA1 Mutation Causes 
Hypomagnesemia
363Nephron 2018;139:359–366
DOI: 10.1159/000488954
KCNA1-p.Leu328Val Results in Non-Functional 
Channel
The effect of the p.Leu328Val mutation on the func-
tion of the encoded Kv1.1 channel was investigated by 
whole-cell patch clamp analysis. HEK293 cells were tran-
siently transfected with mock, Kv1.1 wild type or Kv1.1-
p. Leu328Val. Cells expressing Kv1.1 wild type channels 
produced characteristic outwardly rectifying K+ currents, 
while the expression of Kv1.1-p.Leu328Val resulted in 
small currents similar to control (mock; Fig. 2a, b). The 
current amplitude of Kv1.1-p.Leu328Val, extracted at 
+50 mV, was significantly reduced compared to Kv1.1 
wild type (Fig. 2c). Considering the heterozygosity of this 
de novo mutation, a potential dominant negative effect 
was investigated by co-transfecting HEK293 cells with 
equal amounts of Kv1.1 wild type and Kv1.1-p.Leu-
328Val. The current amplitude of cells co-expressing 
Kv1.1 wild type and Kv1.1-p.Leu328Val was significantly 
reduced compared to that of Kv1.1 wild type alone (p < 
0.05; Fig. 2c). 
KCNA1-p.Leu328Val is Expressed at the Plasma 
Membrane
To examine whether the reduced function of the Kv1.1-
p.Leu328Val channel is due to trafficking failure toward the 
plasma membrane, cell surface biotinylation experiments 
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Fig. 2. Electrophysiological analysis of Kv1.1 wild type and Kv1.1-
p.Leu328Val channels. a Representative original traces of outward 
K+ currents of HEK293 cells expressing mock, Kv1.1 wild type, or 
Kv1.1-p.Leu328Val. The insert on the right top shows the voltage 
protocol consisting of voltage steps from –100 to +50 mV in 10-
mV increments, applied from a holding potential of –80 mV, every 
10 s. b The current-voltage (I/V) relationships of mock (circles), 
Kv1.1 wild type (squares), Kv1.1-p.Leu328Val (triangles). Mean 
values are shown. c Histogram presenting the averaged current 
densities at +50 mV of mock (n = 5), Kv1.1 wild type (n = 12), 
Kv1.1-p.Leu328Val (n = 6), and Kv1.1 wild type + Kv1.1-p.Leu-
328Val (n = 9). Asterisk indicates p < 0.05, compared to Kv1.1 wild 
type. Mean ± SEM is shown.
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were performed. Figure 3a shows a representative immu-
noblot of the biotinylation demonstrating an equal amount 
of Kv1.1 wild type and Kv1.1-p.Leu328Val channels at the 
plasma membrane (upper panel). Furthermore, cells co-
expressing Kv1.1 wild type and Kv1.1-p.Leu328Val showed 
similar plasma membrane abundance as Kv1.1 wild type or 
Kv1.1-p.Leu328Val alone (Fig. 3a). Quantification of 3 in-
dependent experiments confirmed no significant differ-
ences between the conditions (Fig. 3b), suggesting that sim-
ilar amounts of either homotetrameric (wild type or mu-
tant) channels or heterotetrameric (wild type plus mutant) 
channels were located at the plasma membrane. Of note, no 
difference in Kv1.1 expression was observed in the total cell 
lysates (Fig.  3a, middle panel). green fluorescent protein 
(GFP) expression was used as transfection control and was 
equal in all conditions tested (Fig. 3a, lower panel).
Discussion
Here, we describe the first new KCNA1 mutation that 
is causative for hypomagnesemia since the identification 
of the initial family in 2009. A de novo c.982C>G muta-
tion in KCNA1 was identified in a patient with hypomag-
nesemia and tetany. Electrophysiological and biochemi-
cal analyses show that the resulting Kv1.1-p.Leu328Val 
amino acid change causes loss of function, despite normal 
plasma membrane expression. 
The proband presented with hypomagnesemia, tetany, 
muscle weakness, and tremor, which is highly compara-
ble to the Brazilian family described previously [3]. In line 
with this family, the proband showed inappropriately 
normal urinary Mg2+ excretion despite hypomagnesemia 
indicating a renal leak [3]. Treatment with Mg2+ supple-
ments was only partially successful, as it restored the se-
rum Mg2+ concentration to the low-normal range but did 
not completely relieve clinical symptoms. Interestingly, 
the mutation identified here occurred de novo, as its pres-
ence was excluded in all other family members tested in-
cluding the parents. Furthermore, it was not transmitted 
to the unaffected daughter of the patient. These findings 
confirm the causality of KCNA1 mutations for hypomag-
nesemia and demonstrate that this aspect is not muta-
tion-specific for p.Asn255Asp.
KCNA1 mutations have been widely described as cause 
for EA1, with thus far 38 different mutations involved 
[13, 14]. The majority of the mutations result in reduced 
channel function, weakened surface expression, or chang-
es in the biophysical characteristics that lead to a domi-
nant-negative effect upon association with wild-type sub-
units [14]. The latter is also observed in our study. The 
phenotype of EA1 patients is highly heterogeneous and 
may include myokymia, cataplexy, epilepsy, neuromyo-
tonia, paroxysmal dyspnea, and also skeletal defects [13, 
15–20]. Of note, episodic ataxia is not present in all pa-
tients. Despite the identification of the p.Asn255Asp mu-
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Fig. 3. Expression of wild-type and mutant Kv1.1 channels. a Cell 
surface biotinylation of HEK293 cells expressing either mock, 
Kv1.1 wild type, Kv1.1-p.Leu328Val, or co-expressing Kv1.1 wild 
type and Kv1.1-p.Leu328Val. Kv1.1 expression was analyzed by 
immunoblotting for plasma membrane fraction and input from 
the total cell lysates. Representative immunoblot of 4 independent 
experiments is shown. b Bar graph representing the quantification 
of the cell surface biotinylation experiments. It depicts the relative 
plasma membrane expression compared to input, and is shown as 
percentage of Kv1.1 wild type. Mean ± SEM is shown.
KCNA1 Mutation Causes 
Hypomagnesemia
365Nephron 2018;139:359–366
DOI: 10.1159/000488954
tation as cause for hypomagnesemia in 2009 [3], hypo-
magnesemia has not been reported in (other) patients af-
fected by EA1 due to mutations in KCNA1. Therefore, it 
is still difficult to assess the penetrance of the hypomag-
nesemia phenotype in patients with KCNA1 mutations. 
The novel identified KCNA1-p.Leu328Val mutation 
has never been described before. However, closely located 
mutations p.Glu325Asp and p.Leu329Ile have been re-
ported in EA1 patients, in which serum Mg2+ levels are 
unknown [19–21]. The Leu328, as well as these latter 2 
residues, are located on the cytoplasmic side of the trans-
membrane helix S5. The KCNA1-p.Glu325Asp, p.Leu-
328Val, and p.Leu329Ile mutations result only in small 
changes of glutamic acid to aspartic acid and leucine to 
valine or isoleucine, respectively, which are amino acids 
that are similar in size, hydrophobicity, and charge. Based 
on our homology model, they are likely to interact with 
the lipids in the plasma membrane and provide stability 
of the protein complex. Moreover, the amino acid chang-
es might disrupt the S5 helix, which then disturbs the 
channel pore structure and results in reduced channel 
function as apparent in our study. Likewise, the KCNA1 
p.Glu325Asp was shown to significantly alter channel 
function characteristics [22]. Interestingly, the other hy-
pomagnesemia-causing p.Asn255Asp mutation was also 
located at the cytoplasmic interface of the plasma mem-
brane, and demonstrated a similar dominant-negative 
loss of channel function observed in the present study [3]. 
Despite recognition of the wide distribution throughout 
the protein and altered effects on channel properties, there 
is still no clear association reported between the broad 
spectrum of clinical phenotypes and specific mutations. 
Detailed analysis will be necessary to elucidate how func-
tional consequences could explain the disease diversity. 
Although expression levels of Kv1.1 in the kidney are 
low, immunohistochemical stainings have shown that 
Kv1.1 is exclusively expressed at the apical membrane of 
the DCT [3, 5]. In the DCT, intracellular Mg2+ levels are 
comparable to the Mg2+ concentration in the pro-urine 
and therefore a chemical gradient for Mg2+ reabsorption 
is suggested to be virtually absent. It has therefore been 
hypothesized that K+ secretion via Kv1.1 provides an 
electrical gradient that drives Mg2+ reabsorption via 
TRPM6 [3, 4]. Indeed, our previous studies showed that 
Kv1.1 activity determined the membrane potential in 
HEK293 cells [3]. This is in line with studies in rabbit dis-
tal tubule cells showing that the apical K+ conductance 
sets the membrane potential but has been recently con-
tested by experiments in mouse DCT segments that did 
not show apical K+ transport [23, 24]. Recent expression 
studies suggest that expression of Kv1.1 and other K+ 
channels, like ROMK, depend on the specific conditions 
including K+ and Mg2+ availability [25, 26]. Future stud-
ies should aim at resolving the inconsistencies on the ex-
act nature of the apical K+ channel in the DCT. 
In conclusion, this study reports a patient with hypo-
magnesemia and tetany caused by a de novo KCNA1 mu-
tation, unequivocally showing that KCNA1 mutations are 
causative for hypomagnesemia. 
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